Immunome Stock Investor Sentiment

IMNM Stock  USD 8.77  0.16  1.79%   
About 57% of Immunome's investor base is looking to short. The analysis of the overall investor sentiment regarding Immunome suggests that many traders are alarmed. Immunome's investing sentiment overview a quick insight into current market opportunities from investing in Immunome. Many technical investors use Immunome stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Immunome Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Immunome can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at zacks.com         
The Joint Corp. Matches Q4 Earnings Estimates
zacks News
few days ago at news.google.com         
LifeSci Capital Initiates Coverage of Immunome with Outperform Recommendation - Nasdaq
Google News at Macroaxis
few days ago at zacks.com         
Urogen Pharma Reports Q4 Loss, Lags Revenue Estimates
zacks News
over a week ago at businesswire.com         
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over a week ago at finance.yahoo.com         
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over a week ago at businesswire.com         
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over a week ago at businesswire.com         
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over a week ago at www.macroaxis.com         
Acquisition by Rapp Michael of 17500 shares of Immunome at 4.0 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Acquisition by Swain Sandra M of 11333 shares of Immunome at 16.04 subject to Rule 16b-3
Macroaxis News
over two weeks ago at zacks.com         
AbCellera Biologics Inc. Reports Q4 Loss, Misses Revenue Estimates
zacks News
over two weeks ago at finance.yahoo.com         
Immunome to Present at Upcoming March Conferences
Yahoo News
over three weeks ago at thelincolnianonline.com         
Immunome, Inc. Short Interest Update
news
over three weeks ago at gurufocus.com         
Redmile Group, LLCs Strategic Acquisition in Amicus Therapeutics Inc
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Janus Henderson Group PLC Adjusts Position in Immunome Inc
Gurufocus Stories at Macroaxis
over three weeks ago at news.google.com         
Q1 Earnings Forecast for Immunome Issued By Leerink Partnrs - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Immunome that are available to investors today. That information is available publicly through Immunome media outlets and privately through word of mouth or via Immunome internal channels. However, regardless of the origin, that massive amount of Immunome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunome news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunome relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunome's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunome alpha.

Immunome Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of tradable shares by Barchas Isaac of Immunome subject to Rule 16b-3
12/23/2024
2
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635
01/02/2025
3
Immunome prices upsized public offering to raise 150M
01/30/2025
4
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
01/31/2025
5
Immunome Shares Gap Up After Insider Buying Activity
02/04/2025
6
Janus Henderson Group PLC Adjusts Position in Immunome Inc
02/14/2025
7
Immunome to Present at Upcoming March Conferences
02/25/2025
8
Acquisition by Rapp Michael of 17500 shares of Immunome at 4.0 subject to Rule 16b-3
02/28/2025
9
The Joint Corp. Matches Q4 Earnings Estimates
03/13/2025
When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports:
Check out Immunome Hype Analysis, Immunome Correlation and Immunome Performance.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.94)
Revenue Per Share
0.189
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.40)
Return On Equity
(2.76)
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.